Seres Therapeutics (NASDAQ:MCRB) just reported results for the first quarter of 2024.
- Seres Therapeutics reported earnings per share of -27 cents. This was above the analyst estimate for EPS of -34 cents.
- The company did not report any revenue for the quarter.